Description

Danaher Corporation’s Diagnostics Reset: Why Policy Headwinds Are Turning Into Tailwinds!

Danaher Corporation’s fourth-quarter performance in 2025 exhibited a strong finish to the year, marked by better-than-expected performance across its expansive portfolio. A key highlight was the continued strength in the bioprocessing business, as well as improving momentum in Diagnostics and Life Sciences. This was achieved despite a dynamic geopolitical and policy environment. The company reported sales of $6.8 billion for the fourth quarter and 2.5% core revenue growth, with full-year sales reaching $24.6 billion and a core revenue increase of 2%. From a financial perspective, Danaher reported an adjusted operating profit margin of 28.2% for the full year and $7.80 in adjusted diluted net earnings per share, up 4.5% year-over-year. The company’s strong cash generation was evident, with $5.3 billion in free cash flow and a notable 145% free cash flow to net income conversion ratio.